Hematology

General

• Thrombosis Canada Clinical Guides — Thrombosis Canada
• Oral Antithrombotic Agents Overview — RxFiles
• Warfarin Dosing Nomogram — RxFiles

VTE

• Thrombosis Canada Clinical Guides — Thrombosis Canada
• Pulmonary Vascular Guidelines — CHEST 2021
• Perioperative Anti-thrombotic Management — RxFiles
• Pulmonary Embolism Response Team (PERT) Pathways — AHS FMC (Insite login required)
• Acute Pulmonary Embolism Guideline — AHA/ACC 2026
• VTE in Pregnancy

Cancer Associated VTE

• Cancer-Associated VTE Guideline — NCCN
• Cancer-Associated VTE Guideline (2nd Edition) — BSH 2024
• Khorana Score — Risk of VTE in Cancer Patients — MDCalc

Anemia

• Iron Preparations and OTC Products — RxFiles
• IDA Guidelines — BC Guidelines 2023
• ASH IDA Guidelines — ASH 2026
• Ganzoni Equation — Total Iron Deficit for Iron Deficiency Anemia — MDCalc

Anemia of CKD

• CKD Non-Dialysis Anemia — BC Renal 2021
• CKD HD Anemia — BC Renal 2021
• CKD PD Anemia — BC Renal 2021

SFLC

• SFLC Ratio in CKD — (*eg. How to adjust SFLC ratio in the context of CKD*)

VTE

DVT / PE Treatment

• EINSTEIN-PE — Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism — NEJM 2012
• AMPLIFY — Oral Apixaban for the Treatment of Acute Venous Thromboembolism — NEJM 2013
• HOKUSAI-VTE — Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism — NEJM 2013
• COBRRA — Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism — NEJM 2026

Cancer Associated VTE

• Hokusai VTE Cancer — Edoxaban vs. Dalteparin for Cancer-Associated VTE — NEJM 2018
• SELECT-D — Rivaroxaban vs. Dalteparin for Cancer-Associated VTE — JCO 2018
• CARAVAGGIO — Apixaban vs. Dalteparin for Cancer-Associated VTE — NEJM 2020

Cytopenias

• Syndromes of Thrombotic Microangiopathy — NEJM 2014